Review on advanced drug delivery systems: innovations in formulation and delivery technologies
Abstract
Advanced drug delivery systems (DDS) have transformed the pharmaceutical landscape, offering innovative solutions to enhance therapeutic outcomes and patient compliance. This review explores recent advancements in formulation technologies and delivery mechanisms, focusing on nanotechnology, polymeric systems, solid lipid nanoparticles (SLNs), and microparticle-based formulations. Nanotechnology has enabled the development of nanoparticles, liposomes, and nanocrystals that enhance drug solubility, stability, and targeted delivery. Polymeric drug delivery systems, including biodegradable polymers, offer sustained drug release, significantly improving chronic disease management and cancer therapy. SLNs and nanostructured lipid carriers (NLCs) provide stable matrices for drug encapsulation, particularly for lipophilic drugs, while microparticle-based formulations offer controlled and sustained drug release, reducing dosing frequency and enhancing patient compliance. Furthermore, novel delivery mechanisms such as transdermal systems, oral controlled release systems, targeted drug delivery, and inhalable therapies have expanded the possibilities for non-invasive, patient-friendly drug administration. Challenges in scaling up production, regulatory approval, and long-term safety remain significant, but emerging technologies like nanobots and bioengineered tissues hold promise for the future of personalized medicine. As these advanced delivery platforms continue to evolve, they are poised to revolutionize drug delivery, offering more precise, effective, and patient-centric treatments.
References
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71.
3. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-92.
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
5. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
6. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60.
7. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-98.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1-3):149-68.
9. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
10. Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. ChemSoc Rev. 2011;40(1):233-45.
11. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
12. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
13. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. AngewChem Int Ed Engl. 2009;48(5):872-97.
14. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-51.
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
16. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-63.
17. Sailor MJ, Park JH. Hybrid nanoparticles for detection and treatment of cancer. Adv Mater. 2012;24(28):3779-802.
18. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6(3):307-18.
19. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
20. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-66.
21. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Guo R, Chen H. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-32.
22. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3(1):20-31.
23. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005-23.
24. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech 19, 1358–1366 (2018).
25. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia 80, 1211–1224 (2017).
26. Namballa M, Adimulapu A, Jesudasan RE. QbD Assisted Optimization of Microwave-assisted Synthesis of Polyacrylamide Grafted Tragacanth: Characterization and Instrumental Analysis. Current Microwave Chemistry. 2024 Apr 1;11(1):16-29.
27. Kakullamarri PR, Rao KLN (2017) Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs. J BioequivAvailab 9: 439-441.
28. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biological effects. Nanoscale. 2011;3(3):1167-85.
29. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-9.
30. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-91.
31. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
32. Wang F, Yu M, Yan X, Liu X, Zhao Y. Dendrimer-based nanoparticles for cancer diagnosis and therapy. J Control Release. 2017;259:136-48.
33. Wickline SA, Lanza GM. Nanotechnology for molecular imaging and targeted therapy. Circulation. 2003;107(8):1092-5.
34. Ramezani M, Coombes AG, Won R, Pocock G, Davies MC, Duncan R, Illum L, Davis SS. Microglia as a target for drug delivery in multiple sclerosis. J Drug Target. 1997;4(1):65-78.
35. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1(3):193-212.
36. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
37. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21(10):1184-91.
38. Allen TM. Liposomal drug formulations: rationale for development and what we can expect for the future. Drugs. 1998;56(5):747-56.
39. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251-6.
40. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-27.
41. Sahoo SK, Labhasetwar V. Nanotech approaches to delivery and imaging drug. Drug Discov Today. 2003;8(24):1112-20.
42. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. SeminImmunol. 2008;20(2):86-100.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
Most read articles by the same author(s)
- Sanket J Soni , Nanotechnology in pharmaceutical manufacturing: present innovations and future opportunities , Journal of Innovations in Applied Pharmaceutical Science (JIAPS): Volume-9, Issue-3, 2024
.